Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-28-056
Official listed status: posted
Closing information: 2029-11-05 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Official federal synopsis lists an award ceiling of 600,000; applicant-level applicability requires full-NOFO review.
Applicant categories in federal synopsis: City or township governments; Small businesses; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; Native American tribal organizations (other than Federally recognized tribal governments); Public and State controlled institutions of higher education; Public housing authorities/Indian housing authorities; Independent school districts; State governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Native American tribal governments (Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For profit organizations other than small businesses; Special district governments
Federal synopsis
Through this Notice of Funding Opportunity (NOFO), NCI solicits applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the NCI's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC). The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying patients at high risk of PDAC (because of genetic factors, family history and/or the presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; develop molecular- and/or imaging-based markers of pancreatic cysts and determine which lesions are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share …
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.